Literature DB >> 33594104

The Prospective Dutch Colorectal Cancer (PLCRC) cohort: real-world data facilitating research and clinical care.

Jeroen W G Derksen1,2, Geraldine R Vink1,3, Marloes A G Elferink3, Jeanine M L Roodhart1, Helena M Verkooijen4, Wilhelmina M U van Grevenstein5, Peter D Siersema6,7, Anne M May2, Miriam Koopman8.   

Abstract

Real-world data (RWD) sources are important to advance clinical oncology research and evaluate treatments in daily practice. Since 2013, the Prospective Dutch Colorectal Cancer (PLCRC) cohort, linked to the Netherlands Cancer Registry, serves as an infrastructure for scientific research collecting additional patient-reported outcomes (PRO) and biospecimens. Here we report on cohort developments and investigate to what extent PLCRC reflects the "real-world". Clinical and demographic characteristics of PLCRC participants were compared with the general Dutch CRC population (n = 74,692, Dutch-ref). To study representativeness, standardized differences between PLCRC and Dutch-ref were calculated, and logistic regression models were evaluated on their ability to distinguish cohort participants from the Dutch-ref (AU-ROC 0.5 = preferred, implying participation independent of patient characteristics). Stratified analyses by stage and time-period (2013-2016 and 2017-Aug 2019) were performed to study the evolution towards RWD. In August 2019, 5744 patients were enrolled. Enrollment increased steeply, from 129 participants (1 hospital) in 2013 to 2136 (50 of 75 Dutch hospitals) in 2018. Low AU-ROC (0.65, 95% CI: 0.64-0.65) indicates limited ability to distinguish cohort participants from the Dutch-ref. Characteristics that remained imbalanced in the period 2017-Aug'19 compared with the Dutch-ref were age (65.0 years in PLCRC, 69.3 in the Dutch-ref) and tumor stage (40% stage-III in PLCRC, 30% in the Dutch-ref). PLCRC approaches to represent the Dutch CRC population and will ultimately meet the current demand for high-quality RWD. Efforts are ongoing to improve multidisciplinary recruitment which will further enhance PLCRC's representativeness and its contribution to a learning healthcare system.

Entities:  

Mesh:

Year:  2021        PMID: 33594104      PMCID: PMC7887218          DOI: 10.1038/s41598-020-79890-y

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  29 in total

1.  Rethinking pragmatic randomised controlled trials: introducing the "cohort multiple randomised controlled trial" design.

Authors:  Clare Relton; David Torgerson; Alicia O'Cathain; Jon Nicholl
Journal:  BMJ       Date:  2010-03-19

2.  The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.

Authors:  Erik von Elm; Douglas G Altman; Matthias Egger; Stuart J Pocock; Peter C Gøtzsche; Jan P Vandenbroucke
Journal:  Lancet       Date:  2007-10-20       Impact factor: 79.321

Review 3.  Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors.

Authors:  F E Harrell; K L Lee; D B Mark
Journal:  Stat Med       Date:  1996-02-28       Impact factor: 2.373

4.  The role of nonrandomized trials in the evaluation of oncology drugs.

Authors:  R Simon; G M Blumenthal; M L Rothenberg; J Sommer; S A Roberts; D K Armstrong; L M LaVange; R Pazdur
Journal:  Clin Pharmacol Ther       Date:  2015-04-07       Impact factor: 6.875

5.  The New FDA Real-World Evidence Program to Support Development of Drugs and Biologics.

Authors:  David C Klonoff
Journal:  J Diabetes Sci Technol       Date:  2019-03-12

6.  Real-World Evidence and Real-World Data for Evaluating Drug Safety and Effectiveness.

Authors:  Jacqueline Corrigan-Curay; Leonard Sacks; Janet Woodcock
Journal:  JAMA       Date:  2018-09-04       Impact factor: 56.272

7.  Factors Associated With Age Disparities Among Cancer Clinical Trial Participants.

Authors:  Ethan B Ludmir; Walker Mainwaring; Timothy A Lin; Austin B Miller; Amit Jethanandani; Andres F Espinoza; Jacob J Mandel; Steven H Lin; Benjamin D Smith; Grace L Smith; Noam A VanderWalde; Bruce D Minsky; Albert C Koong; Thomas E Stinchcombe; Reshma Jagsi; Daniel R Gomez; Charles R Thomas; C David Fuller
Journal:  JAMA Oncol       Date:  2019-12-01       Impact factor: 31.777

8.  Harnessing the patient voice in real-world evidence: the essential role of patient-reported outcomes.

Authors:  Melanie J Calvert; Daniel J O'Connor; Ethan M Basch
Journal:  Nat Rev Drug Discov       Date:  2019-09       Impact factor: 84.694

9.  ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.

Authors:  E Van Cutsem; A Cervantes; R Adam; A Sobrero; J H Van Krieken; D Aderka; E Aranda Aguilar; A Bardelli; A Benson; G Bodoky; F Ciardiello; A D'Hoore; E Diaz-Rubio; J-Y Douillard; M Ducreux; A Falcone; A Grothey; T Gruenberger; K Haustermans; V Heinemann; P Hoff; C-H Köhne; R Labianca; P Laurent-Puig; B Ma; T Maughan; K Muro; N Normanno; P Österlund; W J G Oyen; D Papamichael; G Pentheroudakis; P Pfeiffer; T J Price; C Punt; J Ricke; A Roth; R Salazar; W Scheithauer; H J Schmoll; J Tabernero; J Taïeb; S Tejpar; H Wasan; T Yoshino; A Zaanan; D Arnold
Journal:  Ann Oncol       Date:  2016-07-05       Impact factor: 32.976

10.  Data Rich, Information Poor: Can We Use Electronic Health Records to Create a Learning Healthcare System for Pharmaceuticals?

Authors:  Hans-Georg Eichler; Brigitte Bloechl-Daum; Karl Broich; Paul Alexander Kyrle; Jillian Oderkirk; Guido Rasi; Rui Santos Ivo; Ad Schuurman; Thomas Senderovitz; Luke Slawomirski; Martin Wenzl; Valerie Paris
Journal:  Clin Pharmacol Ther       Date:  2018-10-14       Impact factor: 6.875

View more
  1 in total

1.  Physical Activity Is Associated with Improved Overall Survival among Patients with Metastatic Colorectal Cancer.

Authors:  Karel C Smit; Jeroen W G Derksen; Geerard L O Beets; Eric J Th Belt; Maaike Berbée; Peter Paul L O Coene; Hester van Cruijsen; Marjan A Davidis; Jan Willem T Dekker; Joyce M van Dodewaard-de Jong; Annebeth W Haringhuizen; Helgi H Helgason; Mathijs P Hendriks; Ronald Hoekstra; Ignace H J T de Hingh; Jan N M IJzermans; Johan J B Janssen; Joop L M Konsten; Maartje Los; Leonie J M Mekenkamp; Peter Nieboer; Koen C M J Peeters; Natascha A J B Peters; Hans J F M Pruijt; Patricia Quarles van Ufford-Mannesse; Ron C Rietbroek; Anandi H W Schiphorst; Arjan Schouten van der Velden; Ruud W M Schrauwen; Mark P S Sie; Dirkje W Sommeijer; Dirk J A Sonneveld; Hein B A C Stockmann; Marleen Tent; Frederiek Terheggen; Manuel L R Tjin-A-Ton; Liselot Valkenburg-van Iersel; Ankie M T van der Velden; Wouter J Vles; Theo van Voorthuizen; Johannes A Wegdam; Johannes H W de Wilt; Miriam Koopman; Anne M May
Journal:  Cancers (Basel)       Date:  2022-02-16       Impact factor: 6.639

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.